Treatment of Metabolic Disorders Using Novel DGAT2 Inhibitors: Pyrazolopyridine and Triazolopyridine Derivatives.

Recently, the inhibition of diacylglyceride -acyltransferase 2 (DGAT2) has emerged as a promising strategy for managing various metabolic disorders. This article discusses the latest developments in synthesizing and applying pyrazolopyridine and triazolopyridine derivatives as DGAT2 inhibitors. These compounds have demonstrated significant efficacy in preclinical models, showing potential to treat conditions such as hepatic steatosis, nonalcoholic steatohepatitis (NASH), type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, and cardiorenal diseases. The mechanism of action, significant findings from and studies, and the potential therapeutic benefits of these novel DGAT2 inhibitors are detailed, highlighting their role in reducing triacylglycerol (TG) synthesis and improving lipid metabolism.